Researchers are launching the first rigorous test of whether exercise helps people with non-tuberculous mycobacterial pulmonary disease (NTM-PD), a serious chronic lung infection. According to Gram Research analysis, this randomized controlled trial will assign 50 patients to either immediate 6-week exercise or delayed intervention, measuring whether a hybrid program combining supervised and home-based workouts improves oxygen uptake, muscle strength, and quality of life. Results could establish exercise as standard treatment alongside antibiotics.
Researchers are testing whether exercise can help people with non-tuberculous mycobacterial pulmonary disease (NTM-PD), a serious chronic lung infection that weakens muscles and causes fatigue. This new study will have 50 patients do a 6-week exercise program combining aerobic workouts, strength training, and core exercises—one session supervised and six at home. According to Gram Research analysis, this is the first rigorous test of whether exercise can improve fitness, muscle strength, and quality of life in NTM-PD patients. The results could change how doctors treat this debilitating infection beyond just antibiotics.
Key Statistics
A 2026 randomized controlled trial protocol published in BMJ Open will test whether a 6-week hybrid exercise program improves cardiorespiratory fitness in 50 adults with non-tuberculous mycobacterial pulmonary disease, addressing the first-ever rigorous evaluation of exercise efficacy in this rare chronic lung infection.
The exercise intervention comprises one supervised and six home-based sessions per week integrating aerobic, resistance, and core exercises, with intensity adjusted using maximum heart rate determined by cardiopulmonary exercise testing in patients with NTM-PD.
Researchers will measure outcomes at baseline, post-intervention, and 6-month follow-up using objective tests including maximal oxygen uptake (VO₂max), 6-Minute Walk Test, 30-Second Sit-to-Stand, and validated quality-of-life questionnaires in this single-center NTM-PD exercise trial.
The Quick Take
- What they studied: Whether a 6-week exercise program can improve heart and lung fitness in people with NTM-PD, a rare chronic lung infection caused by unusual bacteria.
- Who participated: 50 adults with diagnosed non-tuberculous mycobacterial pulmonary disease, split into two groups—one starting exercise immediately and one waiting 6 weeks.
- Key finding: This is a protocol study (the plan for research), not yet completed results. It will measure whether supervised and home-based exercise improves oxygen uptake, muscle strength, walking ability, and quality of life in NTM-PD patients.
- What it means for you: If successful, this research could show that exercise—not just medications—helps people with this serious lung infection feel stronger and live better. However, results won’t be available until the study completes.
The Research Details
This is a randomized controlled trial, which is the gold standard for testing whether a treatment works. Fifty patients with NTM-PD will be randomly assigned to two groups: one group starts a 6-week exercise program right away, while the other group continues their normal care and waits 6 weeks before exercising. This comparison helps researchers know whether improvements come from the exercise itself, not from other factors.
The exercise program is a “hybrid” design, meaning it combines supervised and unsupervised workouts. Patients will attend one supervised session per week at a hospital or clinic where a trainer watches their form and adjusts intensity. They’ll also do six home-based sessions weekly, following a circuit that includes aerobic exercise (like walking or cycling), resistance training (light weights or bands), and core strengthening. A fitness test will determine each person’s safe exercise intensity based on their maximum heart rate.
Researchers will also provide nutrition education and walking training to address the muscle loss and weakness common in NTM-PD. They’ll track adherence through daily exercise diaries and measure outcomes at the start, after 6 weeks, and again at 6 months to see if benefits last.
NTM-PD is a serious chronic infection requiring long-term antibiotics that can cause side effects. The disease itself causes fatigue, shortness of breath, and inactivity, which leads to muscle loss and weakness—and low muscle mass is linked to higher death rates. Currently, treatment focuses only on antibiotics. This study matters because it’s the first rigorous test of whether exercise can address the physical decline that antibiotics alone don’t fix. If exercise helps, it could become a standard part of treatment.
This study has strong design features: it’s randomized (reducing bias), uses a control group (delayed intervention), measures multiple outcomes (fitness, strength, lung function, quality of life), and includes a follow-up period. The study is registered with ClinicalTrials.gov (NCT06488495) and approved by an institutional review board, ensuring ethical oversight. However, it’s a single-center study with only 50 participants, so results may not apply to all populations. The open-label design (participants know they’re exercising) could introduce bias, though the primary outcome (oxygen uptake) is objectively measured.
What the Results Show
This is a protocol paper describing the study plan, not the actual results. The primary outcome being measured is maximal oxygen uptake (VO₂max), which reflects how efficiently the heart and lungs deliver oxygen during exercise. This will be measured using a cardiopulmonary exercise test (CPET), an objective, standardized test.
Secondary outcomes include practical measures of daily function: the 6-Minute Walk Test (how far someone can walk in 6 minutes), the 30-Second Sit-to-Stand test (how many times someone can stand up from a chair in 30 seconds), and the Short Physical Performance Battery (a combination of balance, walking speed, and strength tests). Researchers will also measure lung function using spirometry (breathing tests), muscle mass using bioelectrical impedance analysis, and quality of life using validated questionnaires specific to lung disease and mental health.
Assessments occur at baseline (before exercise starts), immediately after the 6-week program, and at a 6-month follow-up to determine if improvements persist. The study design allows researchers to compare the immediate exercise group to the delayed group, controlling for natural disease progression and other factors.
Beyond fitness improvements, the study will evaluate whether exercise reduces anxiety and depression (common in chronic lung disease), improves nutritional status and muscle mass, and enhances overall quality of life. These outcomes matter because NTM-PD patients often experience psychological distress from chronic illness and physical limitations. The 6-month follow-up is particularly important—it will show whether benefits fade after the supervised program ends or whether patients maintain improvements through continued home exercise.
This is the first randomized controlled trial of exercise in NTM-PD patients. Previous research shows exercise helps people with other chronic lung diseases like cystic fibrosis and COPD (chronic obstructive pulmonary disease), improving fitness and quality of life. However, NTM-PD is less common and has different characteristics, so evidence from other lung diseases may not directly apply. This study fills an important gap by testing whether similar exercise benefits occur in NTM-PD.
This is a protocol study, so actual results aren’t yet available. The study includes only 50 participants at a single hospital, which limits how broadly results apply to diverse populations. The open-label design means participants know they’re exercising, which could influence outcomes like quality of life through placebo effects. The 6-week intervention is relatively short—longer programs might show greater benefits. Finally, the study doesn’t compare exercise to other non-pharmacological treatments, so we won’t know if exercise is better than alternatives like nutrition support alone.
The Bottom Line
This study hasn’t produced results yet, so no clinical recommendations can be made. However, the research design is sound and addresses an important gap. Once completed, results may support exercise as part of standard NTM-PD treatment. Currently, people with NTM-PD should discuss exercise with their doctor before starting any program, as individual fitness levels and disease severity vary greatly.
This research is most relevant to people with NTM-PD, their families, and healthcare providers treating this condition. Pulmonologists, respiratory therapists, and infectious disease specialists should follow this study. People with other chronic lung diseases may also benefit from results, as exercise principles often transfer across conditions. General readers interested in how exercise treats serious infections should find this relevant.
The study is currently enrolling participants and will take approximately 12-18 months to complete data collection and analysis. Peer-reviewed results will likely be published in 2027-2028. Even after publication, it may take 1-2 years for findings to influence clinical practice guidelines.
Frequently Asked Questions
What is non-tuberculous mycobacterial pulmonary disease and why does it cause weakness?
NTM-PD is a chronic lung infection caused by unusual bacteria that requires long-term antibiotics. The infection causes fatigue, shortness of breath, and inactivity, leading to muscle loss and weakness. Low muscle mass increases mortality risk, making physical rehabilitation important alongside medication.
How does the exercise program in this study work?
The 6-week program combines one supervised weekly session at a hospital with six home-based workouts. Each session includes aerobic exercise (walking, cycling), resistance training (weights or bands), and core strengthening. Intensity is personalized based on each patient’s maximum heart rate from a fitness test.
When will we know if exercise actually helps NTM-PD patients?
This is a protocol study describing the research plan. Data collection will take 12-18 months, with peer-reviewed results likely published in 2027-2028. The study measures oxygen uptake, walking distance, muscle strength, and quality of life at 6 weeks and 6 months.
Can people with NTM-PD start exercising now or should they wait for results?
People with NTM-PD should discuss exercise with their doctor before starting, as individual disease severity and fitness levels vary. This study will provide evidence-based guidance, but current research from similar lung diseases suggests exercise is likely beneficial when properly supervised.
Why is this the first study testing exercise in NTM-PD patients?
NTM-PD is rare, so research funding and patient populations are limited. Exercise benefits are proven in other chronic lung diseases like COPD and cystic fibrosis, but NTM-PD has different characteristics requiring its own rigorous testing before recommending exercise as standard treatment.
Want to Apply This Research?
- Track weekly exercise sessions completed (target: 7 per week—1 supervised, 6 home-based), noting type (aerobic, resistance, or core) and duration. Also track daily step count and perceived energy level (1-10 scale) to monitor real-world activity changes.
- Users could set a weekly reminder for their supervised session, schedule home workouts at consistent times, and use the app to log completion with brief notes on how they felt. The app could provide circuit exercise videos and adjust intensity recommendations based on heart rate data.
- Long-term tracking should include monthly fitness assessments (6-minute walk distance, sit-to-stand repetitions), quarterly quality-of-life check-ins, and ongoing adherence monitoring. Users could compare baseline measurements to 6-week and 6-month milestones to visualize progress.
This article describes a research protocol (study plan) for a clinical trial that has not yet produced results. The study is not yet complete, and findings are not yet available. This information is for educational purposes only and should not be used for medical decision-making. People with non-tuberculous mycobacterial pulmonary disease should consult their healthcare provider before starting any exercise program, as individual disease severity, current medications, and fitness levels require personalized medical guidance. This article does not constitute medical advice.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.